Daily Diversion Prevention Insights
Practical, evidence-based insights for pharmacy diversion programs — updated daily.
Closing the Loop on Return-to-Stock Discrepancies
Reconcile returned-to-stock quantities against the original dispensing record and the physical count before restocking, not after — discrepancies caught post-shelving are far harder to trace to a source.
Waste Documentation and Independent Witness Requirements
Wasting controlled substances alone, or with a witness who doesn't actually watch the syringe emptied and disposed of, defeats the control entirely. Require witnesses to observe the full waste event, not just co-sign afterward.
Patient Complaints: An Underused Diversion Signal
A pattern of complaints that a specific medication 'isn't working' or arrives short could signal tampering or substitution rather than a supply issue — route these reports to compliance, not just customer service.
DEA Renewal Lapses: A Hidden Diversion Blind Spot
A lapsed DEA registration for any prescriber or the pharmacy itself can silently disable controlled substance ordering checks—verify renewal dates 60 days out, not at expiration.
Compounding Room Accountability: Witness Every Waste Event
Require two staff to witness and sign every controlled-substance waste event in the compounding room—single-signature logs are the easiest control to falsify.
Auditing Pharmacy Tech Access to Controlled Substances
Review pharmacy tech system permissions regularly — access should match current job duties, and any override or unlock privilege beyond that scope is a red flag worth investigating immediately.
Closing the Loop on Return-to-Stock Discrepancies
When a returned dose is credited back to inventory without a second verifier confirming vial, quantity, and condition match the original dispense, discrepancies slip through unnoticed.
Audit Witness Pairing Patterns to Close Waste Documentation Gaps
Collusion risk rises when the same two employees consistently pair for waste witnessing. Audit co-signer combinations routinely — identical pairings may indicate a gap in your diversion prevention controls.
Patient Complaints: A Frequently Overlooked Drug Diversion Signal
Patient complaints about medications not working, missing doses, or receiving altered capsules can signal active diversion — route these reports to compliance, not just clinical staff.
Closing ADC Reporting Gaps Before Diversion Takes Root
ADC override transactions that go unreviewed for days create silent gaps where diversion hides. Verify your program reviews all unresolved discrepancies and overrides within a defined, documented timeframe.
Who Resolves Your Controlled Substance Count Discrepancies?
Consistent count discrepancies resolved by the same staff member are a red flag, not a coincidence. Audit who signs off on overages and shortages — the pattern matters more than the individual variance.
Verify Prescriber DEA Registrations on Every Controlled Substance Rx
Verify that prescriber DEA registrations on incoming controlled substance prescriptions are currently active — expired DEA numbers on Rx can indicate prescription fraud or active diversion.
Closing Accountability Gaps in the Compounding Room
Compounding rooms with controlled substances require documented ingredient reconciliation — every gram in should match every unit out. Unexplained yield variances are a red flag that warrants immediate investigation.
Auditing Pharmacy Tech Access to Controlled Substance Systems
Pharmacy technicians should have role-based access limited to their workflow area. Regularly audit whether tech credentials can access dispensing records beyond their assigned duties — shared logins mask accountability.
Post-Op Analgesia Audits: Spot Diversion Before It Escalates
During post-op analgesia audits, cross-reference documented pain scores against opioid administration records — consistent full-dose dispensing with low or absent pain documentation is a diversion red flag.
Auditing Return-to-Stock Entries to Catch Controlled Substance Diversion
Unwitnessed return-to-stock entries for controlled substances are a common diversion vector. Require dual verification and same-day wastage documentation to close this gap.
Blind Witnessing: A Hidden Gap in Waste Documentation
Blind witnessing — when a colleague signs off on waste without observing the disposal — is a common diversion gap. Confirm your policy requires the witness to be physically present and observe the full waste event.
Patient Complaints: An Overlooked Signal in Diversion Detection Programs
When patients report that their pain medication isn't working or that pills look different, these complaints may signal diversion. Route patient feedback systematically to your diversion program for review.
Closing the Loop on ADC Discrepancy Report Reviews
ADC discrepancy reports lose their value if reviewed weekly instead of daily — overrides and unwitnessed wastes compound quickly. Ask: who is accountable for reviewing each report, and how often?
Why Controlled Substance Count Reconciliation Stops Diversion Early
Unexplained count discrepancies — even small ones — can signal diversion. Review controlled substance count records daily and investigate any variance before the next shift ends.
Lapsed DEA Registrations: A Pharmacy Diversion Red Flag
Confirm prescriber DEA registrations are current before dispensing controlled substances. A lapsed registration may signal a provider who lost authority but continues writing — a classic diversion red flag.
Compounding Room Accountability: A Critical Drug Diversion Blind Spot
Compounding rooms require two-person verification for every controlled substance batch. Unexplained yield discrepancies between bulk ingredients used and finished product quantities are a key diversion warning sign.
Audit Pharmacy Tech Access Controls to Catch Diversion Early
Pharmacy techs should each have unique credentials scoped to their role — shared logins eliminate individual accountability and make it nearly impossible to trace diversion.
Spotting Diversion Through Post-Op Opioid Waste Audits
In post-op settings, compare administered opioid doses against patient pain scores — unexplained discrepancies or consistently high waste rates for specific providers may indicate diversion at the point of care.
Tamper-Evident Packaging: A First Line of Diversion Defense
Inspect tamper-evident seals on returned or wasted medications — broken, resealed, or swapped packaging is a known diversion indicator that visual checks alone may miss without documented verification.
Return-to-Stock Discrepancies: A Silent Controlled Substance Diversion Risk
When controlled substances are returned to stock without a witness signature or proper documentation, the gap creates an undetected diversion pathway. Audit RTS entries against dispensing records regularly.
Patient-Owned Medications: Closing the Verification and Diversion Gap
When patients bring medications from home, controlled substances in that supply are a diversion target — verify contents on admission, apply tamper-evident seals, and document any discrepancies immediately.
Patient Complaints: An Underutilized Drug Diversion Detection Signal
Patient complaints about inadequate pain relief — particularly recurring complaints tied to a specific dispenser or shift — can serve as an early indicator of drug diversion before any discrepancy appears in controlled substance logs. Diversion programs should establish a formal process for routing patient complaints about pain management to the pharmacy compliance team, not just clinical leadership. Reviewing whether complaint patterns correlate with specific staff, time periods, or patient populations adds a behavioral layer to detection that purely transactional audits often miss. Programs should ask themselves: do we have a mechanism to cross-reference patient grievance data against controlled substance administration records?
How does your program measure up?
Use the free DivertGuard assessment to score your hospital’s diversion prevention controls across 8 domains.
Run the free assessmentLast reviewed: September 2026 · Content is educational, not legal advice.